Skip to main content

Ranolazine Disease Interactions

There are 3 disease interactions with ranolazine:


Ranolazine (applies to ranolazine) severe hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Plasma concentrations of ranolazine increased by 30% in patients with mild (Child-Pugh Class A), and by 60% in patients with moderate (Child-Pugh B) hepatic impairment. The use of ranolazine is contraindicated in patients with clinically significant hepatic impairment.


Ranolazine (applies to ranolazine) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Ranolazine prolongs the QT interval in a dose-related manner. Caution should be exercised if used in patients with long QT interval, or using other QT- prolonging drugs.


Ranolazine (applies to ranolazine) renal disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%, Caution is advised when used in patients with renal impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.

Ranolazine drug interactions

There are 480 drug interactions with ranolazine

Ranolazine alcohol/food interactions

There is 1 alcohol/food interaction with ranolazine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.